Table 1.
Characteristics of participants in the eDelphi and consensus meeting
| Participants registered (n = 479) (%) | Participants completing R1 and included in next rounds (n = 410) (%) | Participants consensus meeting (n = 42) (%) | |
|---|---|---|---|
| Stakeholder groupa | |||
| Doctors | 335 (69·9) | 302 (73·7) | 19 (45·2) |
| Nurses | 30 (6·3) | 21 (5·1) | 6 (14·3) |
| Patients | 76 (15·9) | 52 (12·7) | 6 (14·3) |
| Researchers | 16 (3·3) | 16 (3·9) | 3 (7·1) |
| Industry | 16 (3·3) | 14 (3·4) | 8 (19·1) |
| Regulatory bodies | 6 (1·3) | 5 (1·2) | – |
| Age (years) | |||
| 18–30 | 38 (7·8) | 24 (5·9) | – |
| 31–40 | 124 (25·9) | 102 (24·9) | – |
| 41–50 | 145 (30·3) | 125 (30·5) | – |
| 51–60 | 125 (26·1) | 114 (27·8) | – |
| > 60 | 47 (9·8) | 45 (11) | – |
| Sex | |||
| Female | 300 (62·6) | 249 (60·7) | 25 (60) |
| Male | 177 (37) | 159 (38·8) | 17 (40) |
| Other | 2 (0·4) | 2 (0·5) | – |
| Countries (according to continent) | |||
| Africa | 3 (0·6) | 1 (0·2) | – |
| Asia | 54 (11·3) | 49 (12) | – |
| Europe | 348 (72·7) | 292 (71·2) | 39 (92·8) |
| North America | 35 (7·3) | 33 (8) | 1 (2·4) |
| Oceania | 34 (7·1) | 30 (7·3) | – |
| South America | 5 (1) | 5 (1·2) | 2 (4·8) |
| Total countries participating | 39 | 36 | 13 |
| Characteristics of healthcare professionals (i.e. doctors and nurses) | |||
| Current position | |||
| University teaching hospital | 288 (78·9) | 260 (80·4) | – |
| Other hospital | 48 (13·2) | 38 (11·8) | – |
| Community setting | 19 (5·2) | 18 (5·6) | – |
| Other, e.g. private practice | 10 (2·7) | 7 (2·2) | – |
| Age group of patients with AEs that participants predominantly care for | |||
| Paediatric | 208 (57) | 183 (56·7) | – |
| Adult | 151 (41·4) | 137 (42·4) | – |
| N/A (retired, university setting without patients) | 6 (1·6) | 3 (0·9) | – |
| Experience in care of patients with AEs | |||
| < 10 years | 113 (31) | 98 (30·3) | – |
| > 10 years | 248 (67·9) | 224 (69·3) | – |
| Did not answer | 4 (1·1) | 1 (0·3) | – |
| Membership of international dermatology society or AE interest group | |||
| Yes | 246 (67·4) | 224 (69·3) | – |
| No | 116 (31·8) | 98 (30·3) | – |
| Did not answer | 3 (0·8) | 1 (0·3) | – |
AE, atopic eczema; N/A, not applicable; R, round
aParticipants themselves decided their stakeholder group from a drop‐down menu.